Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009

Regado Biosciences to Present at the Lazard Capital Markets 6th Annual
Healthcare Conference on November 17, 2009

BASKING RIDGE, N.J., Nov. 12 /PRNewswire/ -- Regado Biosciences, a privately
held company leading the development of antithrombotic aptamers with active
control agents, announced that David Mazzo, PhD, CEO and President, will be
presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at
the St. Regis Hotel in New York City. Dr. Mazzo's presentation will be given
at 1:10pm (EST) on Tuesday, November 17 and will include an overview of the
Company's pipeline with emphasis on the lead development program, the
anticoagulant system, REG1. This conference is well attended and will include
several hundred institutional investors with more than one hundred healthcare
management teams presenting.

ABOUT REGADO BIOSCIENCES
Regado Biosciences is pioneering a new therapeutic technology with the
creation and development of two-component drug systems. Each system comprises
a nuclease-stabilized RNA aptamer that can be controlled directly by its
specific and complementary oligonucleotide active control agent. This
technology is being applied to injectable antithrombotics, including
anticoagulants and antiplatelet agents, a multi-billion dollar market in need
of therapeutics with improved safety profiles and a greater degree of
therapeutic control. Regado's technology is designed to give physicians the
ability to actively and directly control each system's therapeutic effect
providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2
Regado's lead program, the anticoagulant system REG1, consists of two
parenteral agents both administered by IV bolus, the first being a potent
highly selective Factor IXa inhibitor (RB006) and the second being its
complementary active control agent (RB007). RB007 can be used to selectively
completely or partially reverse the anticoagulant effect of RB006. REG1,
presently in phase 2b clinical trial, is intended for application in arterial
thrombosis applications, initially in Acute Coronary Syndrome patients
undergoing Percutaneous Coronary Intervention. REG2, Regado's second product
candidate, consists of a subcutaneously administered formulation of RB006
paired with the IV bolus formulation of RB007. REG2 is currently undergoing
phase 1 clinical testing and is intended for use in venous thrombosis
indications.

ABOUT APTAMERS
RB006 is a member of a class of compounds called aptamers. Aptamers are single
stranded oligonucleotides that adopt a specific conformation enabling direct,
specific inhibition of the targeted protein. A key unique feature of aptamers
derives from the fact that they are formed from nucleic acids. As such, their
pharmacologic activity can be controlled by a matched, complementary
oligonucleotide active control agent (the Watson-Crick base pair complement of
a fraction of the agent to be controlled), which can bind to the aptamer,
removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.

SOURCE Regado Biosciences

Ellen McDonald, Chief Business Officer, Regado Biosciences, +1-908-580-2113,
emcdonald@regadobio.com